Nicoletta Pizzardi

Suggest Changes
We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
7100 Background: The incidence of cutaneous adverse effect during therapy with ZD1839, usually dose-dependent, is reported from 48% to 65% with the dose of 250 mg/day. Despite neither dose reduction(More)
  • 1